SYNCOM FORMULATIONS (INDIA) Financial Statement Analysis
|
||
The Revenues of SYNCOM FORMULATIONS (INDIA) have increased by 2.09% YoY .
The Earnings Per Share (EPS) of SYNCOM FORMULATIONS (INDIA) has decreased by -8.70 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
SYNCOM FORMULATIONS (INDIA) Last 5 Annual Financial Results
[BOM: 524470|NSE : SYNCOMF]
Consolidated | Mar2023 | Mar2022 | Mar2017 | Mar2016 | Mar2015 |
---|---|---|---|---|---|
Revenues | ₹224 Cr | ₹220 Cr | ₹185 Cr | ₹184 Cr | ₹173 Cr |
Expenses | ₹204 Cr | ₹200 Cr | ₹168 Cr | ₹167 Cr | ₹155 Cr |
Operating Profit (Excl OI) | ₹20 Cr | ₹20 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr |
Other Income | ₹15 Cr | ₹12 Cr | ₹2.79 Cr | ₹2.67 Cr | ₹1.98 Cr |
Interest | ₹3.40 Cr | ₹1.93 Cr | ₹0.33 Cr | ₹0.14 Cr | ₹0.29 Cr |
Depreciation | ₹4.54 Cr | ₹3.95 Cr | ₹3.12 Cr | ₹3.00 Cr | ₹3.40 Cr |
Profit Before Tax | ₹27 Cr | ₹26 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
Profit After Tax | ₹20 Cr | ₹20 Cr | ₹11 Cr | ₹10 Cr | ₹9.76 Cr |
Consolidated Net Profit | ₹20 Cr | ₹20 Cr | ₹11 Cr | ₹10 Cr | ₹9.76 Cr |
Earnings Per Share (Rs) | ₹0.21 | ₹0.23 | ₹0.13 | ₹0.13 | ₹0.13 |
PAT Margin (%) | 8.95 | 9.01 | 5.70 | 5.58 | 5.62 |
ROE(%) | 8.48 | 11.83 | 9.32 | 9.91 | 9.99 |
ROCE(%) | 9.68 | 13.72 | 13.28 | 14.72 | 15.55 |
Total Debt/Equity(x) | 0.32 | 0.27 | 0.11 | 0.05 | 0.06 |
Key Financials |
||
Market Cap | : | ₹ 1,297.2 Cr |
Revenue (TTM) | : | ₹ 249.8 Cr |
Net Profit(TTM) | : | ₹ 26.4 Cr |
EPS (TTM) | : | ₹ 0.3 |
P/E (TTM) | : | 49.2 |
Industry Peers & Returns | 1W | 1M | 1Y |
SYNCOM FORMULATIONS (INDIA) | 9.5% | 16.1% | 126.5% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
CIPLA | 4.5% | -3.1% | 52.8% |
DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
MANKIND PHARMA | 2.7% | 12.4% | NA |
TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
LUPIN | 3.1% | -1.1% | 127.4% |
SYNCOM FORMULATIONS (INDIA) Revenues
[BOM: 524470|NSE : SYNCOMF]
Y-o-Y | 2.09 % |
5 Yr CAGR | 6.64 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹224 Cr | 2.09 | |
Mar2022 | ₹220 Cr | 18.85 | |
Mar2017 | ₹185 Cr | 0.50 | |
Mar2016 | ₹184 Cr | 6.06 | |
Mar2015 | ₹173 Cr | - |
SYNCOM FORMULATIONS (INDIA) Operating Profit
[BOM: 524470|NSE : SYNCOMF]
Y-o-Y | -0.67 % |
5 Yr CAGR | 2.24 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹20 Cr | -0.67 | |
Mar2022 | ₹20 Cr | 21.04 | |
Mar2017 | ₹17 Cr | -0.70 | |
Mar2016 | ₹17 Cr | -8.46 | |
Mar2015 | ₹18 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -2.74 % |
5 Yr CAGR | -4.13 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 8.87% | -2.74 | |
Mar2022 | 9.12% | 1.79 | |
Mar2017 | 8.96% | -1.10 | |
Mar2016 | 9.06% | -13.71 | |
Mar2015 | 10.5% | - |
SYNCOM FORMULATIONS (INDIA) Profit After Tax
[BOM: 524470|NSE : SYNCOMF]
Y-o-Y | 1.42 % |
5 Yr CAGR | 19.76 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹20 Cr | 1.42 | |
Mar2022 | ₹20 Cr | 87.87 | |
Mar2017 | ₹11 Cr | 1.72 | |
Mar2016 | ₹10 Cr | 6.14 | |
Mar2015 | ₹9.76 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -0.67 % |
5 Yr CAGR | 12.34 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 8.95 % | -0.67 | |
Mar2022 | 9.01 % | 58.07 | |
Mar2017 | 5.7 % | 2.15 | |
Mar2016 | 5.58 % | -0.71 | |
Mar2015 | 5.62 % | - |
SYNCOM FORMULATIONS (INDIA) Earnings Per Share (EPS)
[BOM: 524470|NSE : SYNCOMF]
Y-o-Y | -8.70 % |
5 Yr CAGR | 12.74 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹0.21 | -8.70 | |
Mar2022 | ₹0.23 | 76.92 | |
Mar2017 | ₹0.13 | 0.00 | |
Mar2016 | ₹0.13 | 0.00 | |
Mar2015 | ₹0.13 | - |
SYNCOM FORMULATIONS (INDIA) Return on Capital Employed (ROCE)
[BOM: 524470|NSE : SYNCOMF]
Y-o-Y | -29.45 % |
5 Yr CAGR | -11.17 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 9.68% | -29.45 | |
Mar2022 | 13.72% | 3.31 | |
Mar2017 | 13.28% | -9.78 | |
Mar2016 | 14.72% | -5.34 | |
Mar2015 | 15.55% | - |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
Current Share Price | : | ₹13.8 |
Current MarketCap | : | ₹ 1,297.2 Cr |
Updated EOD on | : | Apr 26,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SYNCOM FORMULATIONS (INDIA) | 9.5% |
16.1% |
126.5% |
SENSEX | 0.9% |
1.5% |
23.6% |
SYNCOM FORMULATIONS (INDIA) related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
S&P BSE SMALL CAP | 4% | 11.6% | 67.3% |
S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
You may also like the below Video Courses
FAQ about SYNCOM FORMULATIONS (INDIA) Financials
How the annual revenues of SYNCOM FORMULATIONS (INDIA) have changed ?
The Revenues of SYNCOM FORMULATIONS (INDIA) have increased by 2.09% YoY .
How the Earnings per Share (EPS) of SYNCOM FORMULATIONS (INDIA) have changed?
The Earnings Per Share (EPS) of SYNCOM FORMULATIONS (INDIA) has decreased by -8.70 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs